HRP20160431T1 - Pirazolo[1,5-a]pirimidini i triazini kao antivirusni agensi - Google Patents
Pirazolo[1,5-a]pirimidini i triazini kao antivirusni agensi Download PDFInfo
- Publication number
- HRP20160431T1 HRP20160431T1 HRP20160431TT HRP20160431T HRP20160431T1 HR P20160431 T1 HRP20160431 T1 HR P20160431T1 HR P20160431T T HRP20160431T T HR P20160431TT HR P20160431 T HRP20160431 T HR P20160431T HR P20160431 T1 HRP20160431 T1 HR P20160431T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- alkyl
- aryl
- compound
- pra
- Prior art date
Links
- 239000003443 antiviral agent Substances 0.000 title 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical class N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 73
- 150000001875 compounds Chemical class 0.000 claims 51
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 50
- 229910017711 NHRa Inorganic materials 0.000 claims 36
- 101150073096 NRAS gene Proteins 0.000 claims 36
- 125000006736 (C6-C20) aryl group Chemical group 0.000 claims 35
- 125000003118 aryl group Chemical group 0.000 claims 25
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 24
- -1 C2-C20 heterocyclyl Chemical group 0.000 claims 22
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 20
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 20
- 229910052799 carbon Inorganic materials 0.000 claims 20
- 150000001721 carbon Chemical group 0.000 claims 20
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 17
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 150000002148 esters Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 11
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 10
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 claims 9
- 125000004043 oxo group Chemical group O=* 0.000 claims 9
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- KSHJXDWYTZJUEI-UHFFFAOYSA-N 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one Chemical compound N=1C2=CC=CC=C2N(CCCCO)C=1CN(C1=O)C2=CN=CC=C2N1C1CC1 KSHJXDWYTZJUEI-UHFFFAOYSA-N 0.000 claims 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108700002314 gontivimab Proteins 0.000 claims 3
- 229960001521 motavizumab Drugs 0.000 claims 3
- 229960000402 palivizumab Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229960000329 ribavirin Drugs 0.000 claims 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- MTPVBMVUENFFLL-HXUWFJFHSA-N 1-(2-fluorophenyl)-3-[(3s)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]urea Chemical compound FC1=CC=CC=C1NC(=O)N[C@@H]1C(=O)NC2=CC=CC=C2C(C=2C=CC=CC=2)=N1 MTPVBMVUENFFLL-HXUWFJFHSA-N 0.000 claims 2
- 241000711904 Pneumoviridae Species 0.000 claims 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- BLUJRJMLDHEMRX-UHFFFAOYSA-N 2-[[2-hydroxy-5-[(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(5-methyltetrazol-1-yl)iminomethyl]phenol Chemical compound Cc1nnnn1N=Cc1ccc(O)c(c1)C(c1ccc(O)cc1)c1cc(C=Nn2nnnc2C)ccc1O BLUJRJMLDHEMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (43)
1. Spoj sa formulom I ili sa formulom II:
[image]
ili farmaceustki prihvatljiva sol ili ester tog spoja,
gdje:
A je -(C(R4)2)n- gdje bilo koji C(R4)2 od spomenutog -(C(R4)2)n- može biti po izboru zamijenjen sa -O-, -S-, -S(O)p-, NH ili NRa;
n je 3, 4, 5 ili 6;
svako p je 1 ili 2;
Ar je C2-C20 heterociklil grupa ili C6-C20 aril grupa, gdje C2-C20 heterociklil grupa ili C6-C20 aril grupa je po izboru supstituirana sa 1 do 5 R6,
X je -C(R13)(R14)-, -N(CH2R14)- ili X je odsutno;
Y je N ili CR7;
svako R1, R2, R3, R4, R5, R6, R7 ili R8 je nezavisno H, okso, OR11, NR11R12,
NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, N3, CN, NO2, SR11, S(O)pRa, NR11S(O)pRa, -C(=O)R11, -C(=O)OR11, -C(=O)NR11R12, -C(=O)SR11, -S(O)p(OR11), -SO2NR11R12, -NR11S(O)p(OR11), -NR11SOpNR11R12, NR11C(=NR11)NR11R12, halogen, (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil;
dva R4 na susjednim atomima ugljika, kada se uzmu zajedno, mogu formirati dvostruku vezu između dva ugljika za koje su oni vezani ili mogu formirati (C3-C7)cikloalkil prsten gdje jedan atom ugljika od spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-, - S-, -S(O)p-, -NH- ili -NRa-;
četiri R4 na susjednim atomima ugljika, kada se uzmu zajedno mogu formirati po izboru supstituirani C6 aril prsten;
dva R4 na istom atomu ugljika, kada se uzmu zajedno mogu formirati (C3-C7)cikloalkil prsten gdje jedan atom ugljika spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-, -S-, -S(O)p-, -NH- ili-NRa-;
dva R6 na susjednim atomima ugljika, kada se uzmu zajedno mogu formirati (C3-C7)cikloalkil prsten gdje jedan atom ugljika iz spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-, -S-, -S(O)p-, -NH- ili -NRa-;
bilo koje R6 susjedno obavezno prisutnoj karbonilnoj grupi spomenute Ar, kada se uzme zajedno sa R3, može formirati vezu ili -(C(R5)2)m- grupu gdje m je 1 ili 2;
bilo koje R6 susjedno obavezno prisutnoj karbonilnoj grupi spomenute Ar, kada se uzme zajedno sa R2, može formirati vezu;
svako Ra je nezavisno (C1-C8)alkil, (C1-C8)haloalkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil gdje je bilo koji (C1-C8)alkil, (C1-C8)haloalkil, (C2-C8)alkenil ili (C2-C8)alkinil od Ra po izboru supstituiran sa jednim ili više OH, NH2, CO2H, C2-C20 heterociklil, i gdje bilo koji aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil od Ra je po izboru supstituiran sa jednim ili više OH, NH2, CO2H, C2-C20 heterociklil ili (C1-C8)alkil;
svako R11 ili R12 je nezavisno H, (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil, (C4-C8)karbociklilalkil, -C(=O)Ra, -S(O)pRa, ili aril(C1-C8)alkil; ili R11 i R12 uzeti zajedno sa azotom za koji su oboje vezani formiraju heterociklični prsten sa 3 do 7 članova gdje bilo koji atom ugljika spomenutog heterocikličnog prstena može biti po izboru zamijenjen sa - O-, -S-, -S(O)p-, -NH-, -NRa- ili -C(O)-;
R13 je H ili (C1-C8)alkil;
R14 je H, (C1-C8)alkil, NR11R12, NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, NR11S(O)pRa, -NR11S(O)p(OR11) ili NR11SOpNR11R12; i
gdje svaki (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil svakog od R1, R2, R3, R4, R5, R6, R7, R8, R11 ili R12 je, nezavisno, po izboru supstituiran sa jednom ili više okso, halogen, hidroksi, NH2, CN, N3, N(Ra)2, NHRa, SH, SRa, S(O)pRa, ORa, (C1-C8)alkil, (C1-C8)haloalkil, -C(O)Ra, -C(O)H, -C(=O)ORa, -C(=O)OH, -C(=O)N(Ra)2, -C(=O)NHRa , -C(=O)NH2, NHS(O)pRa, NRaS(O)pRa, NHC(O)Ra, NRaC(O)Ra, NHC(O)ORa, NRaC(O)ORa, NRaC(O)NHRa, NRaC(O)N(Ra)2, NRaC(O)NH2, NHC(O)NHRa, NHC(O)N(Ra)2, NHC(O)NH2, =NH, =NOH, =NORa, NRaS(O)pNHRa, NRaS(O)pN(Ra)2, NRaS(O)pNH2, NHS(O)pNHRa, NHS(O)pN(Ra)2, NHS(O)pNH2, -OC(=O)Ra, -OP(O)(OH)2 ili Ra.
2. Spoj patentnog zahtjeva 1 koji je spoj sa formulom I.
3. Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 gdje svako R3 je H.
4. Spoj patentnog zahtjeva 1 koji je spoj sa fomulom VII ili spoj sa formulom VIII:
[image]
Ili farmaceutski prihvatljiva sol ili ester tog spoja.
5. Spoj patentnog zahtjeva 4 koji je spoj sa formulom VII.
6. Spoj bilo kojeg od patentnih zahtjeva 1-5 gdje R2 je H.
7. Spoj bilo kojeg od patentnih zahtjeva 1-6 gdje R7 je H, halogen ili (C1-C8)alkil.
8. Spoj bilo kojeg od patentnih zahtjeva 1-7 gdje n je 3 ili 4.
9. Spoj bilo kojeg od patentnih zahtjeva 1-8 gdje svako R4 je nezavisno H ili po izboru supstituiran (C1-C8)alkil, ili četiri R4 na susjednim atomima ugljika, kada se uzmu zajedno, mogu formirati po izboru supstituiran C6 aril prsten.
10. Spoj bilo kojeg od patentnih zahtjeva 1-7 gdje A je -(CH2)3-, -(CH2)4-, -CH2-O-CH2-, -CH2-CH(CH3)-CH2-, -CH2-CH(CF3)-CH2-, -CH2-CH2-CH(CH3)- ili struktura:
[image]
11. Spoj bilo kojeg od patentnih zahtjeva 1-7 gdje A je -(CH2)3-.
12. Spoj bilo kojeg od patentnih zahtjeva 1-11 gdje X je -CR13(NR11C(O)OR11)-, -CR13(NR11R12)-, -CR13(NR11S(O)pRa)- ili je X odsutno.
13. Spoj bilo kojeg od patentnih zahtjeva 1-11 gdje je X odsutno.
14. Spoj bilo kojeg od patentnih zahtjeva 1-13 gdje R1 je H, OR11, NR11R12, CN, (C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil ili (C3-C7)cikloalkil, gdje bilo koji (C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil ili (C3-C7)cikloalkil od R1 je po izboru supstituiran sa jednim ili više okso, halogen, hidroksi, NH2, CN, N3, N(Ra)2, NHRa, SH, SRa, S(O)pRa, ORa, (C1-C8)alkil, (C1-C8)haloalkil, -C(O)Ra, -C(O)H, -C(=O)ORa, -C(=O)OH, -C(=O)N(Ra)2 , -C(=O)NHRa , -C(=O)NH2, NHS(O)pRa, NRaS(O)pRa, NHC(O)Ra, NRaC(O)Ra, NHC(O)ORa, NRaC(O)ORa, NRaC(O)NHRa, NRaC(O)N(Ra)2, NRaC(O)NH2, NHC(O)NHRa, NHC(O)N(Ra)2, NHC(O)NH2, =NH, =NOH, =NORa, NRaS(O)pNHRa, NRaS(O)pN(Ra)2, NRaS(O)pNH2, NHS(O)pNHRa, NHS(O)pN(Ra)2, NHS(O)pNH2, -OC(=O)Ra, -OP(O)(OH)2 ili Ra.
15. Spoj bilo kojeg od patentnih zahtjeva 1-13 gdje R1 je H ili C2-C20 heterociklil, gdje bilo koji C2-C20 heterociklil od R1 je po izboru supstituiran sa jednim ili više okso, halogen, hidroksi, NH2, CN, N3, N(Ra)2, NHRa, SH, SRa, S(O)pRa, ORa, (C1-C8)alkil, (C1-C8)haloalkil, -C(O)Ra, -C(O)H, -C(=O)ORa, -C(=O)OH, -C(=O)N(Ra)2 , -C(=O)NHRa , -C(=O)NH2, NHS(O)pRa, NRaS(O)pRa, NHC(O)Ra, NRaC(O)Ra, NHC(O)ORa, NRaC(O)ORa, NRaC(O)NHRa, NRaC(O)N(Ra)2, NRaC(O)NH2, NHC(O)NHRa, NHC(O)N(Ra)2, NHC(O)NH2, =NH, =NOH, =NORa, NRaS(O)pNHRa, NRaS(O)pN(Ra)2, NRaS(O)pNH2, NHS(O)pNHRa, NHS(O)pN(Ra)2, NHS(O)pNH2, -OC(=O)Ra, -OP(O)(OH)2 ili Ra.
16. Spoj bilo kojeg od patentnih zahtjeva 1-13 gdje R1 je odabrano od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
17. Spoj bilo kojeg od patentnih zahtjeva 1-13 gdje R1 je H ili:
[image]
18. Spoj bilo kojeg od patentnih zahtjeva 1-17 gdje Ar je C6-C20 aril grupa, gdje C6-C20 aril grupa je po izboru supstituirana sa 1 do 5 R6.
19. Spoj bilo kojeg od patentnih zahtjeva 1-17 gdje Ar je fenil po izboru supstituiran sa 1 do 5 R6.
20. Spoj bilo kojeg od patentnih zahtjeva 1-19 gdje svako R6 je nezavisno odabrano od OR11, NR11R12, NR11C(O)R11, NR11C(O)OR11, CN, NR11S(O)pRa, -C(=O)NR11R12, -NR11SOpNR11R12, halogen, (C1-C8)alkil, (C2-C8)alkinil, C6-C20 aril, C2-C20 heterociklil i (C3-C7)cikloalkil, gdje bilo koji C1-C8)alkil, (C2-C8)alkinil, C6-C20 aril, C2-C20 heterociklil i (C3-C7)cikloalkil od R6 je po izboru supstituiran sa jednom ili više okso, halogen, hidroksi, NH2, CN, N3, N(Ra)2, NHRa, SH, SRa, S(O)pRa, ORa, (C1-C8)alkil, (C1-C8)haloalkil, -C(O)Ra, -C(O)H, -C(=O)ORa, -C(=O)OH, -C(=O)N(Ra)2 , -C(=O)NHRa , -C(=O)NH2, NHS(O)pRa, NRaS(O)pRa, NHC(O)Ra, NRaC(O)Ra, NHC(O)ORa, NRaC(O)ORa, NRaC(O)NHRa, NRaC(O)N(Ra)2, NRaC(O)NH2, NHC(O)NHRa, NHC(O)N(Ra)2, NHC(O)NH2, =NH, =NOH, =NORa, NRaS(O)pNHRa, NRaS(O)pN(Ra)2, NRaS(O)pNH2, NHS(O)pNHRa, NHS(O)pN(Ra)2, NHS(O)pNH2, -OC(=O)Ra, -OP(O)(OH)2 ili Ra.
21. Spoj bilo kojeg od patentnih zahtjeva 1-19 gdje svako R6 je nezavisno odabrano od NR11S(O)pRa, NR11C(O)OR11, NR11C(O)R11, (C1-C8)alkil i halogen.
22. Spoj bilo kojeg od patentnih zahtjeva 1-17 gdje Ar je:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
23. Spoj bilo kojeg od patentnih zahtjeva 1-17 gdje Ar je:
[image]
24. Spoj bilo kojeg od patentnih zahtjeva 1-23 gdje R8 je H, NR11R12, NR11C(=NR11)NR11R12, halogen, (C1-C8)alkil, (C2-C8)alkinil, C6-C20 aril, C2-C20 heterociklil ili (C3-C7)cikloalkil, gdje bilo koji (C1-C8)alkil, (C2-C8)alkinil, C6-C20 aril, C2-C20 heterociklil, ili (C3-C7)cikloalkil od R8 je po izboru supstituiran sa jednim ili više okso, halogen, hidroksi, NH2, CN, N3, N(Ra)2, NHRa, SH, SRa, S(O)pRa, ORa, (C1-C8)alkil, (C1-C8)haloalkil, -C(O)Ra, -C(O)H, -C(=O)ORa, -C(=O)OH, -C(=O)N(Ra)2 , -C(=O)NHRa , -C(=O)NH2, NHS(O)pRa, NRaS(O)pRa, NHC(O)Ra, NRaC(O)Ra, NHC(O)ORa, NRaC(O)ORa, NRaC(O)NHRa, NRaC(O)N(Ra)2, NRaC(O)NH2, NHC(O)NHRa, NHC(O)N(Ra)2, NHC(O)NH2, =NH, =NOH, =NORa, NRaS(O)pNHRa, NRaS(O)pN(Ra)2, NRaS(O)pNH2, NHS(O)pNHRa, NHS(O)pN(Ra)2, NHS(O)pNH2, -OC(=O)Ra, -OP(O)(OH)2 ili Ra.
25. Spoj bilo kojeg od patentnih zahtjeva 1-23 gdje R8 je C2-C20 heterociklil, gdje C2-C20 heterociklil je po izboru supstituiran sa jednim ili više okso, halogen, hidroksi, NH2, CN, N3, N(Ra)2, NHRa, SH, SRa, S(O)pRa, ORa, (C1-C8)alkil, (C1-C8)haloalkil, -C(O)Ra, -C(O)H, -C(=O)ORa, -C(=O)OH, -C(=O)N(Ra)2 , -C(=O)NHRa , -C(=O)NH2, NHS(O)pRa, NRaS(O)pRa, NHC(O)Ra, NRaC(O)Ra, NHC(O)ORa, NRaC(O)ORa, NRaC(O)NHRa, NRaC(O)N(Ra)2, NRaC(O)NH2, NHC(O)NHRa, NHC(O)N(Ra)2, NHC(O)NH2, =NH, =NOH, =NORa, NRaS(O)pNHRa, NRaS(O)pN(Ra)2, NRaS(O)pNH2, NHS(O)pNHRa, NHS(O)pN(Ra)2, NHS(O)pNH2, -OC(=O)Ra, -OP(O)(OH)2 ili Ra.
26. Spoj bilo kojeg od patentnih zahtjeva 1-23 gdje R8 je pirolidinil ili azetidinil, gdje pirolidinil ili azetidinil je po izboru supstituiran sa jednim ili više hidroksi, NH2, CN ili -OP(O)(OH)2.
27. Spoj bilo kojeg od patentnih zahtjeva 1-23 gdje R8 je:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
28. Spoj bilo kojeg od patentnih zahtjeva 1-23 gdje R8 je:
[image]
[image]
29. Spoj prema patentnom zahtjevu 1 odabrano iz grupe koja se sastoji od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
i
[image]
i njihovih farmaceustki prihvatljivih soli i estera.
30. Spoj prema patentnom zahtjevu 1 odabran iz grupe koja se sastoji od:
[image]
[image]
[image]
[image]
[image]
i njihovih farmaceustki prihvatljivih soli i estera.
31. Spoj patentnog zahtjeva 1 koji je odabran od
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njihovih farmaceutski prihvatljivih soli ili estera.
32. Spoj patentnog zahtjeva 1 ili njegova farmaceutski prihvatljiva sol ili ester, gdje spoj ima formulu:
[image]
33. Spoj patentnog zahtjeva 1 ili njegova farmaceutski prihvatljiva sol ili ester, gdje spoj ima formulu:
[image]
34. Spoj patentnog zahtjeva 1 ili njegova farmaceutski prihvatljiva sol ili ester, gdje spoj ima formulu:
[image]
35. Farmaceutska kompozicija sadrži spoj sa formulom IX:
[image]
ili njegova farmaceutski prihvatljiva sol ili ester i njegov farmaceutski prihvatljivi nosač.
gdje:
A je -(C(R4)2)n- gdje bilo koji C(R4)2 od spomenutog -(C(R4)2)n- može biti po izboru zamijenjen sa -O-, -S-, S(O)p-, NH ili NRa;
n je 3, 4, 5 ili 6;
svako p je 1 ili 2;
Ar je C2-C20 heterociklil grupa ili C6-C20 aril grupa, gdje C2-C20 heterociklil grupa ili C6-C20 aril grupa je po izboru supstituirana sa 1 do 5 R6;
X je -(CR13R14)-, -N(CH2R14)- ili X je odsutno;
Y je N ili CR7;
svako R1, R2, R3, R4, R5, R6, R7 ili R8 je nezavisno H, okso, OR11, NR11R12, NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, N3, CN, NO2, SR11, S(O)pRa, NR11S(O)pRa, -C(=O)R11, -C(=O)OR11, -C(=O)NR11R12, -C(=O)SR11, -S(O)p(OR11), -SO2NR11R12, -NR11S(O)p(OR11), -NR11SOpNR11R12, NR11C(=NR11)NR11R12, halogen, (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil;
dva R4 na susjednim atomima ugljika, kada se uzmu zajedno, mogu formirati dvostruku vezu između dva atoma ugljika za koje su oni vezani ili mogu formirati (C3-C7)cikloalkil prsten gdje jedan atom ugljika spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-,-S-, -S(O)p-, -NH- ili -NRa-;
četiri R4 na susjednim atomima ugljika, kada su uzeti zajedno, mogu formirati po izboru supstituirani C6 aril prsten;
dva R4 na istom atomu ugljika, kada se uzmu zajedno, mogu formirati (C3-C7)cikloalkil prsten gdje jedan atom ugljika od spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-, -S-, -S(O)p-, -NH- ili -NRa-;
dva R6 na susjednim atomima ugljika, kada se uzmu zajedno, mogu formirati (C3-C7)cikloalkil gdje jedan atom ugljika od spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-, -S-, -S(O)p-, -NH- ili -NRa-;
bilo koji R6 koji je susjedan obaveznoj karbonilnoj grupi spomenute Ar, kada se uzme zajedno sa R3, može formirati vezu ili -(C(R5)2)m- grupu gdje m je 1 ili 2;
bilo koji R6 koji je susjedan obaveznoj karbonilnoj grupi spomenute Ar, kada se uzme zajedno sa R2, može formirati vezu;
svako Ra je nezavisno (C1-C8)alkil, (C1-C8)haloalkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil gdje bilo koji (C1-C8)alkil, (C1-C8)haloalkil, (C2-C8)alkenil ili (C2-C8)alkinil od Ra je po izboru supstituiran sa jednim ili više OH, NH2, CO2H, C2-C20 heterociklil, i gdje bilo koji aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil od Ra je po izboru supstituiran sa jednim ili više OH, NH2, CO2H, C2-C20 heterociklil ili (C1-C8)alkil;
svako R11 ili R12 je nezavisno H, (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil, (C4-C8)karbociklilalkil, -C(=O)Ra, -S(O)pRa, ili aril(C1-C8)alkil; ili R11 i R12 kada se uzmu zajedno sa azotom za koji su oboje vezani formiraju heterociklični prsten sa 3 do 7 članova gdje bilo koji atom ugljika spomenutog heterocikličnog prstena može po izboru biti zamijenjen sa - O-, -S-, -S(O)p-, -NH-, -NRa- ili -C(O)-;
R13 je H ili (C1-C8)alkil;
R14 je H, (C1-C8)alkil, NR11R12, NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, NR11S(O)pRa, -NR11S(O)p(OR11) ili NR11SOpNR11R12; i
gdje svaki (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil od svakog R1, R2, R3, R4, R5, R6, R7, R8, R11 ili R12 je, nezavisno, po izboru supstituiran sa jednim ili više okso, halogen, hidroksi, NH2, CN, N3, N(Ra)2, NHRa, SH, SRa, S(O)pRa, ORa, (C1-C8)alkil, (C1-C8)haloalkil, -C(O)Ra, -C(O)H, -C(=O)ORa, -C(=O)OH, -C(=O)N(Ra)2 , -C(=O)NHRa , -C(=O)NH2 , NHS(O)pRa, NRaS(O)pRa, NHC(O)Ra, NRaC(O)Ra, NHC(O)ORa, NRaC(O)ORa, NRaC(O)NHRa, NRaC(O)N(Ra)2, NRaC(O)NH2, NHC(O)NHRa, NHC(O)N(Ra)2, NHC(O)NH2, =NH, =NOH, =NORa, NRaS(O)pNHRa, NRaS(O)pN(Ra)2, NRaS(O)pNH2, NHS(O)pNHRa, NHS(O)pN(Ra)2, NHS(O)pNH2, -OC(=O)Ra, -OP(O)(OH)2 ili Ra.
36. Farmaceutska kompozicija koja sadrži terapijski efikasnu količinu spoja bilo kojeg od patentnih zahtjeva 1-34 ili njegovu farmaceutski prihvatljivu sol ili ester i farmaceutski prihvatljiv nosač.
37. Farmaceutska kompozicija patentnog zahtjeva 35 ili patentnog zahtjeva 36 dalje sadrži najmanje jedan terapijski agens odabran od ribavirina, palivizumaba, motavizumaba, RSV-IGIV MEDI-557, A-60444, MDT-637, BMS-433771, ALN-RSV0 ili ALX-0171 njihovih mješavina.
38. Spoj sa formulom IX:
[image]
Ili njegova farmaceutski prihvatljiva sol ili ester, ili njegova kompozicija za primjenu u terapiji ili profilaksi Pneumovirinae virusne infekcije ili respiratorne sincicijske virusne infekcije;
gdje:
A je -(C(R4)2)n- gdje bilo koji C(R4)2 spomenutog -(C(R4)2)n- može biti po izboru zamijenjen sa -O-, -S-, S(O)p-, NH ili NRa;
n je 3, 4, 5 ili 6;
svako p je 1 ili 2;
Ar je C2-C20 heterociklil grupa ili C6-C20 aril grupa, gdje C2-C20 heterociklil grupa ili C6-C20 aril grupa je po izboru supstituirana sa 1 do 5 R6;
X je -(CR13R14)-, -N(CH2R14)- ili X je odsutno;
Y je N ili CR7;
svako R1, R2, R3, R4, R5, R6, R7 ili R8 je nezavisno H, okso, OR11, NR11R12, NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, N3, CN, NO2, SR11, S(O)pRa, NR11S(O)pRa, -C(=O)R11, -C(=O)OR11, -C(=O)NR11R12, -C(=O)SR11, -S(O)p(OR11), -SO2NR11R12, -NR11S(O)p(OR11), -NR11SOpNR11R12, NR11C(=NR11)NR11R12 halogen, (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil;
dva R4 na susjednim atomima ugljika, kada su uzeti zajedno, mogu formirati dvostruku vezu između dva ugljika za koje su vezani ili mogu formirati (C3-C7)cikloalkil prsten gdje jedan atom ugljika spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-,-S-, -S(O)p-, -NH- ili -NRa-;
četiri R4 na susjednim atomima ugljika, kada su uzeti zajedno, mogu formirati po izboru supstituiran C6 aril prsten;
dva R4 na istom atomu ugljika, kada su uzeti zajedno, mogu formirati (C3-C7)cikloalkil prsten gdje jedan atom ugljika od spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-, -S-, -S(O)p-, -NH- ili -NRa-;
dva R6 na susjednim atomima ugljika, kada su uzeti zajedno, mogu formirati (C3-C7)cikloalkil prsten gdje jedan ugljikov atom od spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-, -S-, -S(O)p-, -NH- ili -NRa-;
bilo koji R6 susjedan obavezno prisutnoj karbonilnoj grupi spomenute Ar, kada se uzme zajedno sa R3, može formirati vezu ili -(C(R5)2)m- grupu gdje m je 1 ili 2;
bilo koji R6 susjedan obavezno prisutnoj karbonilnoj grupi spomenute Ar, kada se uzme zajedno sa R2, može formirati vezu;
svako Ra je nezavisno (C1-C8)alkil, (C1-C8)haloalkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil gdje bilo koji (C1-C8)alkil, (C1-C8)haloalkil, (C2-C8)alkenil ili (C2-C8)alkinil od Ra je po izboru supstituiran sa jednim ili više OH, NH2, CO2H, C2-C20 heterociklil, i gdje bilo koji aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil od Ra je po izboru supstituiran sa jednim ili više OH, NH2, CO2H, C2-C20 heterociklil ili (C1-C8)alkil;
svako R11 ili R12 je nezavisno H, (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil, (C4-C8)karbociklilalkil, -C(=O)Ra, -S(O)pRa, ili aril(C1-C8)alkil; ili R11 i R12 uzeti zajedno sa azotom za koji su oboje vezani formiraju heterociklični prsten sa 3 do 7 članova gdje bilo koji ugljikov atom spomenutog heterocikličnog prstena može biti po izboru zamijenjen sa - O-, -S-, -S(O)p-, -NH-, -NRa- ili -C(O)-;
R13 je H ili (C1-C8)alkil;
R14 je H, (C1-C8)alkil, NR11R12, NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, NR11S(O)pRa, -NR11S(O)p(OR11) ili NR11SOpNR11R12; i
gdje svaki (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil od svakog R1, R2, R3, R4, R5, R6, R7, R8, R11 ili R12 je, nezavisno, po izboru supstituiran sa jednim ili više okso, halogen, hidroksi, NH2, CN, N3, N(Ra)2, NHRa, SH, SRa, S(O)pRa, ORa, (C1-C8)alkil, (C1-C8)haloalkil, -C(O)Ra, -C(O)H, -C(=O)ORa, -C(=O)OH, -C(=O)N(Ra)2 , -C(=O)NHRa , -C(=O)NH2 , NHS(O)pRa, NRaS(O)pRa, NHC(O)Ra, NRaC(O)Ra, NHC(O)ORa, NRaC(O)ORa, NRaC(O)NHRa, NRaC(O)N(Ra)2, NRaC(O)NH2, NHC(O)NHRa, NHC(O)N(Ra)2, NHC(O)NH2, =NH, =NOH, =NORa, NRaS(O)pNHRa, NRaS(O)pN(Ra)2, NRaS(O)pNH2, NHS(O)pNHRa, NHS(O)pN(Ra)2, NHS(O)pNH2, -OC(=O)Ra, -OP(O)(OH)2 ili Ra.
39. Spoj iz bilo kojeg od patentnih zahtjeva 1-34 ili njegova farmaceutski prihvatljiva sol ili ester, ili njegova kompozicija za primjenu u terapijskom ili profilaktičkom tretmanu Pneumovirinae virusne infekcije ili respiratorne sincicijske virusne infekcije.
40. Spoj ili kompozicija za primjenu patentnih zahtjeva 38 ili 39 dalje sadrži administriranje terapijski efikasne količine najmanje jednog terapijskog agensa ili njegove kompozicije koji je izabran iz grupe koja se sastoji od ribavirina, palivizumaba, motavizumaba, RSV-IGIV, MEDI-557, A-60444, MDT-63, BMS-433771, ALN-RSV0 i ALX-0171 ili njihovih mješavina.
41. Spoj sa formulom IX:
[image]
ili njegova farmaceutski prihvatljiva sol ili ester, ili njegova kompozicija za primjenu u medicinskom liječenju,
gdje:
A je -(C(R4)2)n- gdje bilo koji C(R4)2 spomenutog -(C(R4)2)n- može biti po izboru zamijenjen sa -O-, -S-, S(O)p-, NH ili NRa;
n je 3, 4, 5 ili 6;
svako p je 1 ili 2;
Ar je C2-C20 heterociklil grupa ili C6-C20 aril grupa, gdje C2-C20 heterociklil grupa ili C6-C20 aril grupa je po izboru supstituirana sa 1 do 5 R6;
X je -(CR13R14)-, -N(CH2R14)- ili X je odsutno;
Y je N ili CR7;
svako R1, R2, R3, R4, R5, R6, R7 ili R8 je nezavisno H, okso, OR11, NR11R12, NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, N3, CN, NO2, SR11, S(O)pRa, NR11S(O)pRa, -C(=O)R11, -C(=O)OR11, -C(=O)NR11R12, -C(=O)SR11, -S(O)p(OR11), -SO2NR11R12, -NR11S(O)p(OR11), -NR11SOpNR11R12, NR11C(=NR11)NR11R12, halogen, (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil;
dva R4 na susjednim atomima ugljika, kada se uzmu zajedno, mogu formirati dvostruku vezu između dva ugljika za koje su oni vezani ili mogu formirati (C3-C7)cikloalkil prsten gdje jedan ugljikov atom spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-, - S-, -S(O)p-, -NH- ili -NRa-;
dva R4 na susjednim atomima ugljika, kada se uzmu zajedno, mogu formirati po izboru supstituirani C6 aril prsten;
dva R4 na istom ugljikovom atomu, kada se uzmu zajedno, mogu formirati (C3-C7)cikloalkil prsten gdje jedan atom ugljika spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-, -S-, -S(O)p-, -NH- ili -NRa-;
dva R6 na susjednim atomima ugljika, kada se uzmu zajedno, mogu formirati (C3-C7)cikloalkil prsten gdje jedan atom ugljika od spomenutog (C3-C7)cikloalkil prstena može biti po izboru zamijenjen sa -O-, -S-, -S(O)p-, -NH- ili -NRa-;
bilo koji R6 koji je susjedan obavezno prisutnoj karbonilnoj grupi spomenute Ar, kada se uzme zajedno sa R3, može formirati vezu ili -(C(R5)2)m- grupu gdje m je 1 ili 2;
bilo koji R6 koji je susjedan obavezno prisutnoj karbonilnoj grupi spomenute Ar. kada se uzme zajedno sa R2, može formirati vezu;
svako Ra je nezavisno (C1-C8)alkil, (C1-C8)haloalkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil gdje bilo koji (C1-C8)alkil, (C1-C8)haloalkil, (C2-C8)alkenil ili (C2-C8)alkinil od Ra je po izboru supstituiran sa jednim ili više OH, NH2, CO2H, C2-C20 heterociklil, i gdje bilo koji aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili (C4-C8)karbociklilalkil od Ra je po izboru supstituiran sa jednim ili više OH, NH2, CO2H, C2-C20 heterociklil ili (C1-C8)alkil;
svako R11 ili R12 je nezavisno H, (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil, (C4-C8)karbociklilalkil, -C(=O)Ra, -S(O)pRa, ili aril(C1-C8)alkil; ili R11 i R12 kada se uzmu zajedno sa azotom za koji su oboje vezani formiraju heterociklični prsten sa 3 do 7 članova gdje bilo koji ugljikov atom spomenutog heterocikličnog prstena može biti po izboru zamijenjen sa - O-, -S-, -S(O)p-, -NH-, -NRa- ili -C(O)-;
R13 je H ili (C1-C8)alkil;
R14 je H, (C1-C8)alkil, NR11R12, NR11C(O)R11, NR11C(O)OR11, NR11C(O)NR11R12, NR11S(O)pRa, -NR11S(O)p(OR11) ili NR11SOpNR11R12; i
gdje svaki (C1-C8)alkil, (C2-C8)alkenil, (C2-C8)alkinil, aril(C1-C8)alkil, C6-C20 aril, C2-C20 heterociklil, (C3-C7)cikloalkil ili(C4-C8)karbociklilalkil svakog R1, R2, R3, R4, R5, R6, R7, R8, R11 ili R12 je, nezavisno, po izboru supstituiran sa jednim ili više okso, halogen, hidroksi, NH2, CN, N3, N(Ra)2, NHRa, SH, SRa, S(O)pRa, ORa, (C1-C8)alkil, (C1-C8)haloalkil, -C(O)Ra, -C(O)H, -C(=O)ORa, -C(=O)OH, -C(=O)N(Ra)2, -C(=O)NHRa , -C(=O)NH2 , NHS(O)pRa, NRaS(O)pRa, NHC(O)Ra, NRaC(O)Ra, NHC(O)ORa, NRaC(O)ORa, NRaC(O)NHRa, NRaC(O)N(Ra)2, NRaC(O)NH2, NHC(O)NHRa, NHC(O)N(Ra)2, NHC(O)NH2, =NH, =NOH, =NORa, NRaS(O)pNHRa, NRaS(O)pN(Ra)2, NRaS(O)pNH2, NHS(O)pNHRa, NHS(O)pN(Ra)2, NHS(O)pNH2, -OC(=O)Ra, -OP(O)(OH)2 ili Ra.
42. Spoj bilo kojeg od patentnih zahtjeva 1 do 34 ili njegova farmaceutski prihvatljiva sol ili ester ili njegova kompozicija za primjenu u medicinskom liječenju.
43. Spoj ili kompozicija za primjenu patentnog zahtjeva 41 ili patentnog zahtjeva 42 dalje obuhvaća administriranje terapijski efikasne količine najmanje jednog drugačijeg terapijskog agensa ili njegove kompozicije koji je izabran iz grupe koja se sastoji od ribavirina, palivizumaba, motavizumaba, RSV-IGIV, MEDI-557, A-60444, MDT-63, BMS-433771, ALN-RSV0 i ALX-0171 ili njihovih mješavina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35812210P | 2010-06-24 | 2010-06-24 | |
PCT/US2011/041688 WO2011163518A1 (en) | 2010-06-24 | 2011-06-23 | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
EP11729018.9A EP2585467B1 (en) | 2010-06-24 | 2011-06-23 | Pyrazolo[1,5-a]pyrimidines and -triazines as antiviral agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160431T1 true HRP20160431T1 (hr) | 2016-05-20 |
Family
ID=44509853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160431TT HRP20160431T1 (hr) | 2010-06-24 | 2016-04-21 | Pirazolo[1,5-a]pirimidini i triazini kao antivirusni agensi |
Country Status (38)
Country | Link |
---|---|
US (7) | US8486938B2 (hr) |
EP (2) | EP2585467B1 (hr) |
JP (4) | JP5878171B2 (hr) |
KR (1) | KR101970837B1 (hr) |
CN (2) | CN102958933B (hr) |
AP (1) | AP3417A (hr) |
AR (1) | AR082275A1 (hr) |
AU (1) | AU2011270798B2 (hr) |
BR (1) | BR112012033117A2 (hr) |
CA (1) | CA2800834C (hr) |
CL (1) | CL2012003632A1 (hr) |
CO (1) | CO6640297A2 (hr) |
CR (1) | CR20130023A (hr) |
CY (1) | CY1118239T1 (hr) |
DK (1) | DK2585467T3 (hr) |
EA (2) | EA201591390A1 (hr) |
EC (2) | ECSP13012400A (hr) |
ES (2) | ES2571334T3 (hr) |
HK (3) | HK1223934A1 (hr) |
HR (1) | HRP20160431T1 (hr) |
HU (1) | HUE029174T2 (hr) |
IL (2) | IL223253B (hr) |
MA (1) | MA34392B1 (hr) |
ME (1) | ME02397B (hr) |
MX (1) | MX2012015292A (hr) |
NZ (1) | NZ604345A (hr) |
PE (1) | PE20130395A1 (hr) |
PL (1) | PL2585467T3 (hr) |
PT (1) | PT3012258T (hr) |
RS (1) | RS54761B1 (hr) |
SG (2) | SG10201505022WA (hr) |
SI (1) | SI2585467T1 (hr) |
SM (1) | SMT201600155B (hr) |
TW (3) | TWI537272B (hr) |
UA (1) | UA112292C2 (hr) |
UY (1) | UY33467A (hr) |
WO (1) | WO2011163518A1 (hr) |
ZA (1) | ZA201209549B (hr) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011221075B2 (en) * | 2010-02-26 | 2013-12-19 | Mitsubishi Tanabe Pharma Corporation | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors |
SG10201505022WA (en) * | 2010-06-24 | 2015-07-30 | Gilead Sciences Inc | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
KR101875238B1 (ko) | 2010-06-24 | 2018-07-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 포스포디에스테라아제 (pdes) 저해제로서의 융합 헤테로시클릭 화합물 |
EP2635278B1 (en) | 2010-11-03 | 2019-12-11 | Dow AgroSciences LLC | Pesticidal compositions and processes related thereto |
EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
JP5531066B2 (ja) * | 2011-08-24 | 2014-06-25 | 田辺三菱製薬株式会社 | ピラゾロピリミジン化合物及びpde10阻害剤としてのその使用 |
MX355431B (es) | 2011-10-26 | 2018-04-18 | Dow Agrosciences Llc | Composiciones plaguicidas y procesos relacionados con dichas composiciones. |
AU2012358805B2 (en) | 2011-12-22 | 2017-07-20 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
DK2838900T3 (da) * | 2012-04-17 | 2019-10-14 | Gilead Sciences Inc | Forbindelser og fremgangsmåder til antiviral behandling |
US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
JP6463670B2 (ja) | 2012-04-27 | 2019-02-06 | ダウ アグロサイエンシィズ エルエルシー | 農薬組成物およびそれらに関する方法 |
US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
CA2889919C (en) | 2012-11-16 | 2021-08-17 | University Health Network | Pyrazolopyrimidine compounds |
ES2946360T3 (es) | 2012-12-07 | 2023-07-17 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de ATR quinasa para el tratamiento de enfermedades de cáncer |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8969360B2 (en) | 2013-03-15 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
RU2019101889A (ru) | 2013-03-15 | 2019-03-28 | Версеон Корпорейшн | Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз |
WO2014175370A1 (ja) * | 2013-04-25 | 2014-10-30 | 塩野義製薬株式会社 | ピロリジン誘導体およびそれらを含有する医薬組成物 |
BR112016003348B1 (pt) | 2013-08-21 | 2023-03-07 | Alios Biopharma, Inc | Compostos antivirais ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e seus usos |
WO2015058024A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
CA2925954A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
US9108946B2 (en) | 2013-10-17 | 2015-08-18 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
US9102654B2 (en) | 2013-10-17 | 2015-08-11 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
EP3057428A4 (en) | 2013-10-17 | 2017-05-17 | Dow AgroSciences LLC | Processes for the preparation of pesticidal compounds |
EP3057431A4 (en) | 2013-10-17 | 2017-04-05 | Dow AgroSciences LLC | Processes for the preparation of pesticidal compounds |
WO2015058020A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
JP2016535026A (ja) | 2013-10-22 | 2016-11-10 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
AR098100A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones plaguicidas y los métodos relacionados |
NZ719776A (en) | 2013-10-22 | 2017-06-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
AU2014340432B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
MX2016005310A (es) | 2013-10-22 | 2016-08-08 | Dow Agrosciences Llc | Composiciones pesticidas sinergicas y metodos relacionados. |
AU2014340413B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
RU2656888C2 (ru) | 2013-10-22 | 2018-06-07 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Пестицидные композиции и связанные с ними способы |
EP3060055A4 (en) | 2013-10-22 | 2017-03-29 | Dow AgroSciences LLC | Synergistic pesticidal compositions and related methods |
AU2014340409B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
US9144241B2 (en) | 2013-10-22 | 2015-09-29 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
JP2016534068A (ja) | 2013-10-22 | 2016-11-04 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
CN105792651A (zh) | 2013-10-22 | 2016-07-20 | 美国陶氏益农公司 | 杀虫组合物和与其相关的方法 |
US9491944B2 (en) | 2013-10-22 | 2016-11-15 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
TW201519779A (zh) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | 協同性殺蟲組成物及相關方法(十二) |
RU2656889C2 (ru) | 2013-10-22 | 2018-06-07 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Пестицидные композиции и соответствующие способы |
TW201519776A (zh) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | 協同性殺蟲組成物及相關方法(八) |
TW201517797A (zh) | 2013-10-22 | 2015-05-16 | Dow Agrosciences Llc | 協同性殺蟲組成物及相關方法(十一) |
RU2687276C2 (ru) | 2013-12-06 | 2019-05-13 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, пригодные для использования в качестве ингибиторов atr киназы |
LT3152212T (lt) | 2014-06-05 | 2020-05-11 | Vertex Pharmaceuticals Inc. | Radioaktyviai žymėti 2-amino-6-fluor-n-[5-fluor-piridin-il]- pirazolo[1,5-a]pirimidin-3-karboksamido junginio dariniai, naudingi kaip atr kinazės inhibitoriai, minėto junginio gamybos būdas ir jo skirtingos kietos formos |
GB201410817D0 (en) | 2014-06-17 | 2014-07-30 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D | Therapeutic agents |
SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
RU2017105470A (ru) * | 2014-07-22 | 2018-08-22 | Элиос Биофарма, Инк. | Способы лечения парамиксовирусов |
EP3174856A4 (en) | 2014-07-31 | 2018-01-10 | Dow AgroSciences LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
WO2016018443A1 (en) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
CA2954631A1 (en) | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
US20160045528A1 (en) * | 2014-08-05 | 2016-02-18 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
EP3183238A4 (en) | 2014-08-19 | 2018-01-10 | Dow AgroSciences LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
WO2016039781A1 (en) | 2014-09-12 | 2016-03-17 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
CA2960790A1 (en) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
CN107207512B (zh) * | 2014-12-08 | 2019-09-10 | 爱尔兰詹森科学公司 | 对呼吸道合胞病毒(rsv)的复制具有抑制活性的哌啶取代的三环吡唑并[1,5-a]嘧啶衍生物 |
WO2016091774A1 (en) | 2014-12-08 | 2016-06-16 | Janssen Sciences Ireland Uc | Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv) |
ES2892123T3 (es) | 2014-12-26 | 2022-02-02 | Univ Emory | Derivados antivíricos de N4-hidroxicitidina |
MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
US10532995B2 (en) | 2015-02-27 | 2020-01-14 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
JP2018076234A (ja) * | 2015-03-16 | 2018-05-17 | 大正製薬株式会社 | ピラゾロ[1,5−a]ピリミジン化合物 |
JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
EP3507290A1 (en) | 2016-08-31 | 2019-07-10 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
CN110325036B (zh) | 2016-12-29 | 2021-10-26 | 美国陶氏益农公司 | 用于制备杀虫化合物的方法 |
US10100033B2 (en) | 2016-12-29 | 2018-10-16 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
WO2019067864A1 (en) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV |
TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗rsv活性之吡唑并嘧啶 |
GB2581936B (en) | 2017-12-07 | 2021-02-10 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
JP7305658B2 (ja) | 2018-01-31 | 2023-07-10 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗rsv活性を有するシクロアルキル置換ピラゾロピリミジン |
WO2019206828A1 (en) | 2018-04-23 | 2019-10-31 | Janssen Sciences Ireland Unlimited Company | Heteroaromatic compounds having activity against rsv |
MX2021002569A (es) | 2018-09-06 | 2021-06-08 | Cidara Therapeutics Inc | Composiciones y metodos para el tratamiento de infecciones virales. |
CN112996790B (zh) | 2018-10-30 | 2023-11-03 | 克洛诺斯生物公司 | 用于调节cdk9活性的化合物、组合物和方法 |
WO2020138015A1 (ja) | 2018-12-27 | 2020-07-02 | 大正製薬株式会社 | ピラゾロ[1,5-a]ピリミジン大環状化合物 |
WO2021050612A1 (en) * | 2019-09-09 | 2021-03-18 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of respiratory syncytial virus |
CN116425754A (zh) * | 2021-12-30 | 2023-07-14 | 苏州爱科百发生物医药技术有限公司 | 芳杂双环化合物及其抗病毒用途 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
FR2224175B1 (hr) | 1973-04-04 | 1978-04-14 | Isf Spa | |
US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
DE69233690T2 (de) | 1991-07-02 | 2008-01-24 | Nektar Therapeutics, San Carlos | Abgabevorrichtung für nebelförmige Medikamente |
US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
US5543413A (en) * | 1994-02-25 | 1996-08-06 | Regents Of The University Of Michigan | Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action |
US6342501B1 (en) * | 1994-02-25 | 2002-01-29 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d] pyrimidines as antiviral agents |
JPH10504808A (ja) | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
NZ506417A (en) * | 1998-02-17 | 2003-05-30 | Tularik Inc | Anti-viral pyrimidine derivatives |
US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
TWI225488B (en) | 1999-12-21 | 2004-12-21 | Janssen Pharmaceutica Nv | Derivatives of homopiperidinyl substituted benzimidazole analogues |
BR0308391A (pt) | 2002-03-13 | 2005-01-11 | Pharmacia & Upjohn Co Llc | Derivados de pirazolo(1,5-a)piridina como moduladores neurotransmissores |
ES2287476T3 (es) * | 2002-05-10 | 2007-12-16 | Smithkline Beecham Corporation | Pirazolopirimidinas sustituidas. |
JP4602076B2 (ja) | 2002-06-04 | 2010-12-22 | ネオジェネシス ファーマシューティカルズ インコーポレイテッド | 抗ウイルス剤としてのピラゾロ[1,5a]ピリミジン化合物 |
DE10247271A1 (de) | 2002-10-10 | 2004-08-26 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yle |
EP1697377B1 (en) * | 2003-12-24 | 2011-01-26 | Biota Scientific Management Pty. Ltd. | Polycyclic agents for the treatment of respiratory syncytial virus infections |
SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
TW200831084A (en) | 2006-11-21 | 2008-08-01 | Genelabs Tech Inc | Anti-viral compounds |
AU2008334948B2 (en) | 2007-12-13 | 2014-11-20 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of RSV infection |
JP2011507851A (ja) | 2007-12-19 | 2011-03-10 | ザ スクリプス リサーチ インスティチュート | Rhoキナーゼインヒビターとしてのベンゾイミダゾールおよびアナログ |
KR20100133385A (ko) | 2008-02-26 | 2010-12-21 | 노파르티스 아게 | Cxcr2의 억제제로서의 헤테로시클릭 화합물 |
PE20091838A1 (es) | 2008-04-09 | 2009-12-18 | Infinity Pharmaceuticals Inc | Inhibidores de amida hidrolasa de acido graso |
WO2010033701A2 (en) | 2008-09-19 | 2010-03-25 | Genzyme Corporation | Inhibitors of sphingosine kinase 1 |
EP2182081B1 (de) | 2008-10-29 | 2014-01-22 | Neue Materialien Bayreuth GmbH | Verfahren zur thermischen Behandlung eines beschichteten Stahlblechkörpers |
AU2009322393B2 (en) | 2008-12-03 | 2017-02-02 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
US8609696B2 (en) | 2008-12-18 | 2013-12-17 | Boehringer Ingelheim International Gmbh | Serotonin 5-HT2B receptor inhibitors |
CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
SG174146A1 (en) | 2009-02-27 | 2011-10-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
EP2404902A1 (en) | 2009-03-05 | 2012-01-11 | Shionogi&Co., Ltd. | Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
RS52854B (en) | 2009-06-11 | 2013-12-31 | Abbvie Bahamas Limited | INHIBITOR OF PATITIS C VIRUSA |
WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8623899B2 (en) | 2009-08-07 | 2014-01-07 | Janssen Research & Development Ireland | Bis-benzimidazole derivatives as hepatitis C virus inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
EP2575866A4 (en) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
SG10201505022WA (en) | 2010-06-24 | 2015-07-30 | Gilead Sciences Inc | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
SG186830A1 (en) | 2010-07-22 | 2013-02-28 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
AU2012358805B2 (en) | 2011-12-22 | 2017-07-20 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
DK2838900T3 (da) | 2012-04-17 | 2019-10-14 | Gilead Sciences Inc | Forbindelser og fremgangsmåder til antiviral behandling |
-
2011
- 2011-06-23 SG SG10201505022WA patent/SG10201505022WA/en unknown
- 2011-06-23 MX MX2012015292A patent/MX2012015292A/es active IP Right Grant
- 2011-06-23 EA EA201591390A patent/EA201591390A1/ru unknown
- 2011-06-23 SI SI201130764T patent/SI2585467T1/sl unknown
- 2011-06-23 EP EP11729018.9A patent/EP2585467B1/en active Active
- 2011-06-23 US US13/167,618 patent/US8486938B2/en active Active
- 2011-06-23 BR BR112012033117A patent/BR112012033117A2/pt not_active Application Discontinuation
- 2011-06-23 RS RS20160349A patent/RS54761B1/sr unknown
- 2011-06-23 NZ NZ604345A patent/NZ604345A/en not_active IP Right Cessation
- 2011-06-23 AU AU2011270798A patent/AU2011270798B2/en active Active
- 2011-06-23 CA CA2800834A patent/CA2800834C/en active Active
- 2011-06-23 ES ES11729018T patent/ES2571334T3/es active Active
- 2011-06-23 EA EA201291172A patent/EA023223B1/ru not_active IP Right Cessation
- 2011-06-23 PT PT15195216T patent/PT3012258T/pt unknown
- 2011-06-23 KR KR1020137001645A patent/KR101970837B1/ko active IP Right Grant
- 2011-06-23 AP AP2013006686A patent/AP3417A/xx active
- 2011-06-23 PE PE2012002481A patent/PE20130395A1/es active IP Right Grant
- 2011-06-23 SG SG2012091112A patent/SG186291A1/en unknown
- 2011-06-23 HU HUE11729018A patent/HUE029174T2/hu unknown
- 2011-06-23 ES ES15195216T patent/ES2700542T3/es active Active
- 2011-06-23 ME MEP-2016-70A patent/ME02397B/me unknown
- 2011-06-23 DK DK11729018.9T patent/DK2585467T3/en active
- 2011-06-23 UA UAA201213827A patent/UA112292C2/uk unknown
- 2011-06-23 WO PCT/US2011/041688 patent/WO2011163518A1/en active Application Filing
- 2011-06-23 PL PL11729018.9T patent/PL2585467T3/pl unknown
- 2011-06-23 EP EP15195216.5A patent/EP3012258B1/en active Active
- 2011-06-23 CN CN201180030620.4A patent/CN102958933B/zh active Active
- 2011-06-23 MA MA35586A patent/MA34392B1/fr unknown
- 2011-06-23 CN CN201610004340.0A patent/CN105481866A/zh active Pending
- 2011-06-23 JP JP2013516776A patent/JP5878171B2/ja active Active
- 2011-06-24 UY UY0001033467A patent/UY33467A/es not_active Application Discontinuation
- 2011-06-24 TW TW103145818A patent/TWI537272B/zh active
- 2011-06-24 TW TW100122237A patent/TWI476201B/zh active
- 2011-06-24 AR ARP110102213A patent/AR082275A1/es unknown
- 2011-06-24 TW TW105109583A patent/TWI626050B/zh active
-
2012
- 2012-11-26 IL IL223253A patent/IL223253B/en active IP Right Review Request
- 2012-11-30 CO CO12217437A patent/CO6640297A2/es active IP Right Grant
- 2012-12-14 ZA ZA2012/09549A patent/ZA201209549B/en unknown
- 2012-12-21 CL CL2012003632A patent/CL2012003632A1/es unknown
-
2013
- 2013-01-21 CR CR20130023A patent/CR20130023A/es unknown
- 2013-01-21 EC ECSP13012400 patent/ECSP13012400A/es unknown
- 2013-05-30 US US13/905,410 patent/US9238039B2/en active Active
- 2013-10-18 HK HK16112263.7A patent/HK1223934A1/zh unknown
- 2013-10-18 HK HK13111752.0A patent/HK1184157A1/zh unknown
- 2013-11-01 US US14/069,685 patent/US8809330B2/en active Active
-
2015
- 2015-07-15 JP JP2015141184A patent/JP6684552B2/ja active Active
-
2016
- 2016-01-14 US US14/995,486 patent/US20160130275A1/en not_active Abandoned
- 2016-04-21 HR HRP20160431TT patent/HRP20160431T1/hr unknown
- 2016-05-31 SM SM201600155T patent/SMT201600155B/it unknown
- 2016-06-01 CY CY20161100485T patent/CY1118239T1/el unknown
- 2016-08-15 HK HK16109754.9A patent/HK1221715A1/zh unknown
- 2016-09-14 JP JP2016179202A patent/JP2017019850A/ja active Pending
- 2016-11-09 US US15/347,494 patent/US20170190708A1/en not_active Abandoned
-
2017
- 2017-06-30 US US15/639,970 patent/US9957275B2/en active Active
- 2017-12-21 EC ECIEPI201784267A patent/ECSP17084267A/es unknown
-
2018
- 2018-02-08 IL IL257410A patent/IL257410A/en unknown
- 2018-03-16 US US15/923,726 patent/US20180298011A1/en not_active Abandoned
-
2019
- 2019-12-18 JP JP2019227963A patent/JP2020059750A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160431T1 (hr) | Pirazolo[1,5-a]pirimidini i triazini kao antivirusni agensi | |
HRP20191754T1 (hr) | Spojevi i postupci za antivirusno liječenje | |
HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
HRP20171050T1 (hr) | Derivati 1,3-dihidro-2h-benzimidazol-2-ona supstituirani s heterociklima kao antivirusna sredstva za respiratorni sincicijski virus | |
HRP20140370T1 (hr) | 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman | |
HRP20210038T1 (hr) | Pirolopirimidini za uporabu u infekciji virusom gripe | |
JP2015506348A5 (hr) | ||
SI2704721T1 (en) | ACTIVATORS PIANO KINASE FOR USE IN THERAPY | |
HRP20151000T1 (hr) | Antivirusni spojevi | |
RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
CL2013003647A1 (es) | Compuestos derivados de pirrolo[2,3-d] pirimidina o pirrolo[2,3-b]piridina, inhibidores de la actividad de jak; composicion farmaceutica; utiles para el tratamiento de enfermedades autoinmunitarias, inflamatorias y de reabsorcion osea, cancer, trastornos mieloproliferativos o rechazo a trasplante de organos. | |
HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
JP2017537949A5 (hr) | ||
EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
EA201492204A1 (ru) | Нуклеозиды на основе урацила и спирооксетана | |
HRP20160641T1 (hr) | Fuzionirani triciklički spojevi kao inhibitori raf kinaze | |
AR078012A1 (es) | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus | |
MD4551C1 (ro) | Derivaţi pe bază de tetrahidroizochinoline şi N-(fenilfosfat)amide, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
WO2012116290A3 (en) | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
CU20120082A7 (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para uso como principio activo farmacéutico | |
NZ593475A (en) | Calcium salts for reducing exhalation of infectious bioaerosol particles | |
EA201491525A1 (ru) | Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae | |
HRP20191322T1 (hr) | Antitumorska kombinacija koja sadži kabazitaksel i cisplatin | |
SI3083605T1 (en) | COMPOUNDS OF FLUOROFENYL PIRAZOLE | |
SI2858987T1 (en) | PREPARATION OF 5-PHENYL-4- (PYRIDIN-2-ILLETHYLAMINO) -CHUINAZOLIN-2-YL) -PIRIDIN-3-SULPHONAMIDE PHOSPHORAMIDIC ACID |